Skip to content

Discontinued — last reported Q4 '22

Free cash flow at other companies

Amgen logo
AmgenAMGN
$1.48B+50.7%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$119.69M-6.6%
Nuvation Bio logo
Nuvation BioNUVB
$5.02M+112%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$6.11M+173%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$3M+1,296%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$7.33M+251%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Calculated from Rigel Pharmaceuticals’s reported figures.

The official record: Rigel Pharmaceuticals’s 10-K, filed March 4, 2025, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's free cash flow?
Rigel Pharmaceuticals (RIGL) reported free cash flow of -$21.98M in Q4 2022.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.